Pfizer/BioNTech Covid Vaccine – Questions and Answers
- How did they make the vaccine so quickly?
- What is in the mRNA Covid-19 vaccine?
- I heard that the COVID-19 vaccines contain microchips, is this true?
- Will receiving the mRNA vaccine alter my DNA?
- Is it safer to contract COVID-19 naturally as opposed to getting vaccinated?
- Will getting the vaccine give me Covid-19?
- I have had Covid-19; do I still need the vaccine?
- I have a strong immune system, and I don’t usually catch a cold, should I worry about catching COVID-19?
- What is the duration of the vaccine? How long will it last?
- How many does of this Covid-19 vaccine will I need?
- What are the potential side effects of getting vaccinated?
- What is the advice for those who suffer from allergies?
- What is the advice for pregnant or breastfeeding women?
- Can I transmit COVID-19 after vaccination?
- Who will get the vaccine first?
- What about vaccinating children?
- How do mRNA vaccines work and how are they different to previously used vaccines?
- How effective is the vaccine?
- Do I need the vaccine to travel?
- What percentage of the population needs to be vaccinated to have herd immunity against Covid-19?
- Do I need to wear a mask when receiving the vaccine?
- When can I stop wearing a mask and a resume close contact with others after I have had the vaccine?
A misconception is that work on the vaccine began when the pandemic started; scientists had already begun research for coronavirus vaccines during previous outbreaks caused by related coronaviruses such as SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome). That earlier research provided a head start for rapid development of vaccines to protect against infection with the novel coronavirus SARS-CoV2, the virus that causes COVID-19.
Making a vaccine is expensive and funding is a common issue, but as the pandemic increased with worldwide spread so did the resources made available to research teams.
The different stages of the vaccine development process have also overlapped; such that manufacturing was already underway whilst the clinical trials were still ongoing, further speeding up the process.
Pfizer BioNTech COVID-19 vaccine is a nucleoside-modified messenger RNA vaccine (mRNA) vaccine. mRNA vaccines use the pathogen’s genetic code as the vaccine; this then exploits the host cells to translate the code and then make the target spike protein. The protein then acts as an intracellular antigen to stimulate the immune response. The mRNA is then normally degraded within a few days.
Pfizer BioNTech COVID-19 vaccine has been generated entirely in the laboratory, outside of living cells, formulated in lipid nanoparticles. The vaccine contains the following ingredients:
- mRNA (messenger ribonucleic acid = a single-stranded RNA molecule that is complementary to one of the DNA strands of a gene).
- Lipids / fats
ALC-0315 = (4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), – ALC-0159 = 2[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, – 1,2-Distearoyl-sn-glycero-3-phosphocholine, 5 – cholesterol,
– potassium chloride, – potassium dihydrogen phosphate, – sodium chloride, – disodium hydrogen phosphate dihydrate,
The vaccine contains less than 1 mmol (39 mg) of potassium per dose, i.e. it is considered essentially ‘potassium-free’. It also contains less than 1 mmol sodium (23 mg) per dose, so is considered essentially ‘sodium-free’.
No, the COVID-19 vaccines do not contain microchips.
mRNA stands for messenger ribonucleic acid and can be described as ‘instructions for how to make a protein or even just a piece of a protein’. mRNA is not able to The mRNA from a COVID-19 vaccine never enter the nucleus of the cell, which is where our DNA are kept and therefore cannot alter or modify a person’s genetic makeup (DNA). Instead, COVID-19 vaccines that use mRNA work with the body’s natural defences to safely develop protection (immunity) to disease.
No it is not safer to contract COVID-19 naturally. Yes, around 80% of people who contract COVID-19 have a mild infection, however there is no guarantee that you will be amongst this group. If you are someone who suffers severe symptoms there is a risk of death due to complications associated with progressive infection. Further, there is emerging evidence that those who have previously recovered from COVID-19, including those who had mild symptoms, may suffer from what is termed long-covid. People with long-covid suffer prolonged symptoms after recovery; symptoms described include malaise or fatigue, muscle or joint pain, headaches, etc which can persist for weeks or months. More seriously, there is emerging evidence that young, low risk patients who continue to have ongoing symptoms of covid-19 have signs of damage to multiple organs months after initially being infected.
No, the Pfizer/BioNTech COVID-19 vaccine does not have any viable virus particles so cannot cause the disease.
Currently, data suggests that immunity to mild COVID-19 infections wane, which means protective serum antibodies that were generated as a result of contracting the infection cannot be detected after a few months. This could mean that you are no longer protected, and therefore will not immune to COVID-19 after this period. It is feasible that COVID-19 re-infection could occur in recovered patients. This is true in other coronavirus infections, especially in those who continue to have increased exposure to the virus.
Getting the vaccine will likely prolong immunity to COVID-19 and provide a better defence against potential long term consequences of natural infection (Long-Covid); therefore, vaccination is recommended to anyone who has recovered from COVID-19 (4 weeks from recovery date).
8. I have a strong immune system, and I don’t usually catch a colds, should I worry about catching COVID-19?
Some of us are healthy and may not be prone to seasonal coughs and colds. This however does not make you immune to catching any viral infections, including COVID-19. Moreover, COVID-19 unlike other coronaviruses that cause coughs and colds, has a higher death rate. COVID-19 can also cause long-term health concerns, even in those who suffer seemingly mild symptoms. A vaccine will soon be available in Gibraltar, it is important that you consider getting a vaccine to protect yourself and encourage those close to you, especially the elderly who have a higher risk of death from COVID-19.
The COVID-19 virus has been around for less than a year to date and so far there is data showing that people who have previously had COVID-19 have some immunity that can last several months’ post infection. This is encouraging. The vaccine has just been rolled out and data will be collected routinely to determine the longevity of COVID-19 immunity. Considering the clinical trials have just recently concluded and some are still ongoing, it is too early to know the length of COVID-19 immunity, both from vaccine or natural infection.
Immunity provided by the Pfizer/BioNTech COVID-19 vaccine appears to reach full effect seven days after the second dose.
It is too early to know if whether this is a one-off injection or an annual one, like that for the ‘flu.
You will need two doses of the Pfizer/BioNTech COVID-19 vaccine; the two injections should be given 21 days apart.
No effective medicine is without side effects so you have to balance the risk and the benefit.
The Pfizer vaccine cuts cases of Covid by about 95%, but can have common side-effects including pain at the injection site, tiredness, headache, muscle pain, chills, joint pain, and fever. These symptoms could affect more than one in 10 people. Some reports from the FDA suggest more people experienced these side effects after receiving the second dose of the vaccine, as opposed to the first.
But it is important to remember these are all symptoms of the immune system responding and working, they can be managed at home with paracetamol.
“Not many of us think twice about driving somewhere, but the risk of a car accident is a lot higher than serious effects of a vaccine…
The danger is people falsely assume health problems that happen by coincidence are caused by the vaccine. But the truth is that people get sick all the time. Every five minutes in the UK one person has a heart attack and one person has a stroke.”
Dr Penny Ward, KCL Faculty of Pharmaceutical Medicine.
Information regarding allergies is continuously being updated based upon data from on-going vaccination programs. Guidance now states that anyone who has had an unexplained anaphylaxis (severe allergic reaction leading to hospitalisation) or is allergic to multiple drugs should not get this vaccine.
The vaccine is suitable for those who are allergic to:
- a single drug (e.g. penicillin, or ibuprofen)
- dust or pollen
In Gibraltar we will have a pre-screening survey for everyone before COVID-19 vaccination. This will determine suitability for the COVID-19 vaccine.
Clinical trials for the Pfizer/ BioNTech vaccine did not include either pregnant or lactating women, and whilst the current evidence raises no inherent concerns for safety in pregnancy more data will need to be obtained before confirming suitability. In view of this, current regulations dictate that women who are pregnant, breastfeeding and/or planning to be pregnant (within the next 2 months) are excluded from the Covid-19 vaccination programme.
Anyone who has an active COVID-19 infection can transmit it. It is currently unknown whether those who have been vaccinated, whilst protected themselves, are still able to transmit the infection to others should they contract COVID-19 naturally/in the community. A large number of people who were involved in the COVID-19 clinical trials are now being monitored to determine transmission after vaccination and we should be able to have this data available in the near future. It is therefore safe to assume that whilst we wait for this data we should follow public health advise about COVID-19 best measures (washing hands, maintaining mask use and physical distancing etc.).
The vaccination program will progress in stages, beginning with the most vulnerable:
|1||Residents in ERS and their carers|
|2||All those 80 years of age and over|
|3||All those 70 years of age and over and front-line health and social care workers|
|4||Clinically extremely vulnerable individuals|
|5||All those 65 years of age and over|
|6||All individuals aged 16 years to 64 years with underlying health conditions which put them at higher risk of serious disease and mortality|
|7||All those 50 – 65 years of age|
|8||All those 16 – 50 years of age, resident in Gibraltar|
|9||All those who are cross frontier workers who are entitled to free healthcare in Gibraltar|
People will be vaccinated twice – around 21 days apart – and full immunity starts seven days after the second dose.
Children will not be a priority group for a vaccine as trials have only just begun in children and therefore there is very limited data on safety and immunogenicity in this group. Moreover, children and young people have a very low risk of suffering the severe health harms associated with complex cases of COVID-19. COVID-19 vaccines are therefore not routinely recommended for children and young people under 18 years of age.
The messenger ribonucleic acid (mRNA) COVID-19 vaccine contains the genetic sequence (mRNA) for the spike protein which is found on the surface of the SARS-CoV-2 virus. The mRNA is wrapped in a lipid envelope (referred to as a nanoparticle) to enable it to be transported into the cells in the body. Lipids provide a well-established delivery system into cells both in normal cell function and during a viral infection.
When injected, the mRNA is taken up by the host’s cells which in turn produce the spike proteins. The spike proteins are then displayed on the surface of the cell. This stimulates the immune system to produce antibodies (proteins that recognise and bind the spike protein) and activate immune memory cells which remain ready for any future exposure to the COVID-19 virus.
As there is no whole or live virus involved, the mRNA vaccine cannot cause disease. The mRNA naturally degrades after a few days.
The phase 3 human trials of the Pfizer BioNTech COVID-19 vaccine demonstrated a vaccine efficacy of 95%, with consistent efficacy across age, gender, and ethnicity. The observed efficacy in adults over 65 years of age was 94%. (Read more here)
As with any vaccine, there will be a few that fall in the percentage that are not fully protected following vaccination. Data is not yet available for individuals with a weakened immune system or who are taking chronic treatment that suppresses or prevents immune responses.
At present the International Air Transport Association (IATA) have not indicated whether vaccination will be a necessary requirement for all journeys abroad, it will be down to individual countries to determine their own requirements for tourists/ residents.
IATA are currently asking governments to consider aviation workers as front-line so they are able to get vaccinated promptly when vaccines are made available.
It is also very likely there will be an impact on the cost of travel insurance for those who are vaccinated (and therefore protected against Covid-19) as opposed to those who are not.
20. What percentage of the population needs to be vaccinated to have herd immunity against Covid-19?
The percentage of people who need to have protection in order to achieve herd immunity varies by disease. Read more on herd immunity HERE.
At present, the percentage of people that would need to get vaccinated to achieve herd immunity to COVID-19 is unknown.
Yes. It is recommended that during the pandemic people wear a mask/face covering that covers their nose and mouth when in contact with others outside your household, including in healthcare facilities, and when receiving any vaccine, including a COVID-19 vaccine. (Note: Anyone who has trouble breathing or is unable to remove a mask without assistance should not wear a mask).
22. When can I stop wearing a mask and a resume close contact with others after I have had the vaccine?
There is not enough information currently available to say if or when Public Health guidance will stop recommending that people wear masks and avoid close contact with others to help prevent the spread of COVID-19. Further studies are needed to understand more about the protection that COVID-19 vaccines provide before making that decision. Other factors (i.e. how many people get vaccinated/how the virus is spreading within the community), will also affect this decision.